Cargando…

Skin models for the testing of transdermal drugs

The assessment of percutaneous permeation of molecules is a key step in the evaluation of dermal or transdermal delivery systems. If the drugs are intended for delivery to humans, the most appropriate setting in which to do the assessment is the in vivo human. However, this may not be possible for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd, Eman, Yousef, Shereen A, Pastore, Michael N, Telaprolu, Krishna, Mohammed, Yousuf H, Namjoshi, Sarika, Grice, Jeffrey E, Roberts, Michael S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076797/
https://www.ncbi.nlm.nih.gov/pubmed/27799831
http://dx.doi.org/10.2147/CPAA.S64788
_version_ 1782462087108231168
author Abd, Eman
Yousef, Shereen A
Pastore, Michael N
Telaprolu, Krishna
Mohammed, Yousuf H
Namjoshi, Sarika
Grice, Jeffrey E
Roberts, Michael S
author_facet Abd, Eman
Yousef, Shereen A
Pastore, Michael N
Telaprolu, Krishna
Mohammed, Yousuf H
Namjoshi, Sarika
Grice, Jeffrey E
Roberts, Michael S
author_sort Abd, Eman
collection PubMed
description The assessment of percutaneous permeation of molecules is a key step in the evaluation of dermal or transdermal delivery systems. If the drugs are intended for delivery to humans, the most appropriate setting in which to do the assessment is the in vivo human. However, this may not be possible for ethical, practical, or economic reasons, particularly in the early phases of development. It is thus necessary to find alternative methods using accessible and reproducible surrogates for in vivo human skin. A range of models has been developed, including ex vivo human skin, usually obtained from cadavers or plastic surgery patients, ex vivo animal skin, and artificial or reconstructed skin models. Increasingly, largely driven by regulatory authorities and industry, there is a focus on developing standardized techniques and protocols. With this comes the need to demonstrate that the surrogate models produce results that correlate with those from in vivo human studies and that they can be used to show bioequivalence of different topical products. This review discusses the alternative skin models that have been developed as surrogates for normal and diseased skin and examines the concepts of using model systems for in vitro–in vivo correlation and the demonstration of bioequivalence.
format Online
Article
Text
id pubmed-5076797
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50767972016-10-31 Skin models for the testing of transdermal drugs Abd, Eman Yousef, Shereen A Pastore, Michael N Telaprolu, Krishna Mohammed, Yousuf H Namjoshi, Sarika Grice, Jeffrey E Roberts, Michael S Clin Pharmacol Review The assessment of percutaneous permeation of molecules is a key step in the evaluation of dermal or transdermal delivery systems. If the drugs are intended for delivery to humans, the most appropriate setting in which to do the assessment is the in vivo human. However, this may not be possible for ethical, practical, or economic reasons, particularly in the early phases of development. It is thus necessary to find alternative methods using accessible and reproducible surrogates for in vivo human skin. A range of models has been developed, including ex vivo human skin, usually obtained from cadavers or plastic surgery patients, ex vivo animal skin, and artificial or reconstructed skin models. Increasingly, largely driven by regulatory authorities and industry, there is a focus on developing standardized techniques and protocols. With this comes the need to demonstrate that the surrogate models produce results that correlate with those from in vivo human studies and that they can be used to show bioequivalence of different topical products. This review discusses the alternative skin models that have been developed as surrogates for normal and diseased skin and examines the concepts of using model systems for in vitro–in vivo correlation and the demonstration of bioequivalence. Dove Medical Press 2016-10-19 /pmc/articles/PMC5076797/ /pubmed/27799831 http://dx.doi.org/10.2147/CPAA.S64788 Text en © 2016 Abd et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Abd, Eman
Yousef, Shereen A
Pastore, Michael N
Telaprolu, Krishna
Mohammed, Yousuf H
Namjoshi, Sarika
Grice, Jeffrey E
Roberts, Michael S
Skin models for the testing of transdermal drugs
title Skin models for the testing of transdermal drugs
title_full Skin models for the testing of transdermal drugs
title_fullStr Skin models for the testing of transdermal drugs
title_full_unstemmed Skin models for the testing of transdermal drugs
title_short Skin models for the testing of transdermal drugs
title_sort skin models for the testing of transdermal drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076797/
https://www.ncbi.nlm.nih.gov/pubmed/27799831
http://dx.doi.org/10.2147/CPAA.S64788
work_keys_str_mv AT abdeman skinmodelsforthetestingoftransdermaldrugs
AT yousefshereena skinmodelsforthetestingoftransdermaldrugs
AT pastoremichaeln skinmodelsforthetestingoftransdermaldrugs
AT telaprolukrishna skinmodelsforthetestingoftransdermaldrugs
AT mohammedyousufh skinmodelsforthetestingoftransdermaldrugs
AT namjoshisarika skinmodelsforthetestingoftransdermaldrugs
AT gricejeffreye skinmodelsforthetestingoftransdermaldrugs
AT robertsmichaels skinmodelsforthetestingoftransdermaldrugs